Study participants received setmelanotide, a melanocortin 4 receptor (MC4R) agonist, once daily via subcutaneous injection for 52 weeks. Overall, 83.3% (95% CI, 58.7-99.8) of patients achieved a ...

These structural motifs can be found in the MC4R antagonist PF-07258669 in phase 1 clinical trials from Pifzer and in the development of the FGFR4 selective inhibitor Roblitinib from Novartis.